Malignant neoplasm of peripheral nerves of upper limb, including shoulder
ICD-10 C47.1 is a billable code used to indicate a diagnosis of malignant neoplasm of peripheral nerves of upper limb, including shoulder.
C47.1 refers to malignant neoplasms that arise from the peripheral nerves in the upper limb, including the shoulder region. These tumors can be classified as soft tissue sarcomas, which are malignant tumors originating from connective tissues, including nerves. The clinical presentation may vary, but symptoms often include pain, swelling, and neurological deficits due to nerve involvement. Diagnosis typically involves imaging studies such as MRI or CT scans, followed by biopsy for histological confirmation. Grading of these tumors is crucial, as it helps determine the aggressiveness of the neoplasm and guides treatment decisions. Multidisciplinary management is essential, involving surgical oncologists, medical oncologists, and radiation oncologists to optimize patient outcomes. Treatment may include surgical resection, chemotherapy, and radiation therapy, depending on the tumor's size, location, and grade. Regular follow-up is necessary to monitor for recurrence or metastasis.
Detailed pathology reports, imaging studies, and treatment plans must be documented.
Diagnosis and management of soft tissue sarcomas, including surgical interventions and chemotherapy regimens.
Accurate staging and grading of tumors are critical for treatment planning.
Surgical notes detailing the extent of resection and any reconstruction performed.
Surgical management of peripheral nerve tumors, including nerve grafting or reconstruction.
Documentation must reflect the functional impact of the tumor and the surgical approach taken.
Used when a malignant peripheral nerve tumor is surgically excised.
Surgical notes must detail the extent of the excision and any reconstruction performed.
Orthopedic and surgical oncology specialties should ensure comprehensive documentation.
Tumor grading is crucial as it indicates the aggressiveness of the malignancy and helps guide treatment decisions. Higher-grade tumors may require more aggressive treatment and closer follow-up.
